Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mazyar Shadman

Showing results (71-80 of 224) with videos related to

Pageof 23
Sort By:
Blood|August 11, 2017
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinibAllison M Winter, Daniel J Landsburg, Anthony R Mato, et al.
Blood Advances|January 24, 2025
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE studyJennifer R Brown, Jessica Li, Barbara F Eichhorst, et al.
Cancers|March 13, 2025
Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAILindsey E Roeker, John M Burke, Joanna M Rhodes, et al.
Oncology and Therapy|June 22, 2026
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLLDaniel A Ermann, Deborah M Stephens, Xiaoliang Wang, et al.
Blood Advances|May 3, 2024
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experienceGulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaChaitra Ujjani, Hongkun Wang, Catherine Broome, et al.
American Journal of Hematology|February 18, 2015
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndromeMazyar Shadman, Raya Mawad, Carol Dean, et al.
Blood Advances|January 10, 2024
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinicRahul Banerjee, Christina Poh, Alexandre V Hirayama, et al.
Blood Advances|September 2, 2021
Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphomaJennifer L Crombie, Loretta J Nastoupil, Robert Redd, et al.
Blood Neoplasia|June 19, 2026
Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphomaLorenzo Iovino, Ningxin Ma, Mohamed A Kharfan-Dabaja, et al.
Pageof 23

Showing results (71-80 of 224) with videos related to

Sort By:
Pageof 23
Blood|August 11, 2017
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinibAllison M Winter, Daniel J Landsburg, Anthony R Mato, et al.
Blood Advances|January 24, 2025
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE studyJennifer R Brown, Jessica Li, Barbara F Eichhorst, et al.
Cancers|March 13, 2025
Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAILindsey E Roeker, John M Burke, Joanna M Rhodes, et al.
Oncology and Therapy|June 22, 2026
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLLDaniel A Ermann, Deborah M Stephens, Xiaoliang Wang, et al.
Blood Advances|May 3, 2024
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experienceGulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaChaitra Ujjani, Hongkun Wang, Catherine Broome, et al.
American Journal of Hematology|February 18, 2015
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndromeMazyar Shadman, Raya Mawad, Carol Dean, et al.
Blood Advances|January 10, 2024
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinicRahul Banerjee, Christina Poh, Alexandre V Hirayama, et al.
Blood Advances|September 2, 2021
Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphomaJennifer L Crombie, Loretta J Nastoupil, Robert Redd, et al.
Blood Neoplasia|June 19, 2026
Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphomaLorenzo Iovino, Ningxin Ma, Mohamed A Kharfan-Dabaja, et al.
Pageof 23